Lucas Reis Correia

Mr. Lucas Reis Correia

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 December 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
GSGiulia Osório Santana
Giulia Osório Santana
RCRodrigo de Macedo Couto
Rodrigo de Macedo Couto
RLRafael Maffei Loureiro
Rafael Maffei Loureiro
BFBrunna Carolinne Rocha Silva Furriel
Brunna Carolinne Rocha Silva Furriel
EREdna Terezinha Rother
Edna Terezinha Rother
LCLucas Reis Correia
Lucas Reis Correia
Background: Traditional health care systems face long-standing challenges, including patient diversity, geographical disparities, and financial constraints. The emergence of artificial intelligence (AI) in health care offers solutions to these challenges. AI, a multidisciplinary field, enhances clinical decision-making. However, imbalanced AI models may enhance health disparities. Objective: This systematic review aims to investigate the economic performance and equity impact of AI in diagnostic imaging for skin, neurological, and pulmonary diseases. The research question is “To what extent does the use of AI in imaging exams for diagnosing skin, neurological, and pulmonary diseases result in improved economic outcomes, and does it promote equity in health care systems?” Methods: The study is a systematic review of economic and equity evaluations following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and CHEERS (Consolidated Health Economic Evaluation Reporting Standards) guidelines. Eligibility criteria include articles reporting on economic evaluations or equity considerations related to AI-based diagnostic imaging for specified diseases. Data will be collected from PubMed, Embase, Scopus, Web of Science, and reference lists. Data quality and transferability will be assessed according to CHEC (Consensus on Health Economic Criteria), EPHPP (Effective Public Health Practice Project), and Welte checklists. Results: This systematic review began in March 2023. The literature search identified 9,526 publications and, after full-text screening, 9 publications were included in the study. We plan to submit a manuscript to a peer-reviewed journal once it is finalized, with an expected completion date in January 2024. Conclusions: AI in diagnostic imaging offers potential benefits but also raises concerns about equity and economic impact. Bias in algorithms and disparities in access may hinder equitable outcomes. Evaluating the economic viability of AI applications is essential for resource allocation and affordability. Policy makers and health care stakeholders can benefit from this review’s insights to make informed decisions. Limitations, including study variability and publication bias, will be considered in the analysis. This systematic review will provide valuable insights into the economic and equity implications of AI in diagnostic imaging. It aims to inform evidence-based decision-making and contribute to more efficient and equitable health care systems. International Registered Report Identifier (IRRID): DERR1-10.2196/48544

13 August 2025 in Interactive Journal of Medical Research
Verified
Journal Article
Open access
GSGiulia Osório Santana
Giulia Osório Santana
RCRodrigo de Macedo Couto
Rodrigo de Macedo Couto
RLRafael Maffei Loureiro
Rafael Maffei Loureiro
BFBrunna Carolinne Rocha Silva Furriel
Brunna Carolinne Rocha Silva Furriel
LPLuis Gustavo Nascimento de Paula
Luis Gustavo Nascimento de Paula
LCLucas Reis Correia
Lucas Reis Correia
Background: Health care systems around the world face numerous challenges. Recent advances in artificial intelligence (AI) have offered promising solutions, particularly in diagnostic imaging. Objective: This systematic review focused on evaluating the economic feasibility of AI in real-world diagnostic imaging scenarios, specifically for dermatological, neurological, and pulmonary diseases. The central question was whether the use of AI in these diagnostic assessments improves economic outcomes and promotes equity in health care systems. Methods: This systematic review has 2 main components, economic evaluation and equity assessment. We used the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) tool to ensure adherence to best practices in systematic reviews. The protocol was registered with PROSPERO (International Prospective Register of Systematic Reviews), and we followed the PRISMA-E (Preferred Reporting Items for Systematic Reviews and Meta-Analyses - Equity Extension) guidelines for equity. Scientific articles reporting on economic evaluations or equity considerations related to the use of AI-based tools in diagnostic imaging in dermatology, neurology, or pulmonology were included in the study. The search was conducted in the PubMed, Embase, Scopus, and Web of Science databases. Methodological quality was assessed using the following checklists, CHEC (Consensus on Health Economic Criteria) for economic evaluations, EPHPP (Effective Public Health Practice Project) for equity evaluation studies, and Welte for transferability. Results: The systematic review identified 9 publications within the scope of the research question, with sample sizes ranging from 122 to over 1.3 million participants. The majority of studies addressed economic evaluation (88.9%), with most studies addressing pulmonary diseases (n=6; 66.6%), followed by neurological diseases (n=2; 22.3%), and only 1 (11.1%) study addressing dermatological diseases. These studies had an average quality access of 87.5% on the CHEC checklist. Only 2 studies were found to be transferable to Brazil and other countries with a similar health context. The economic evaluation revealed that 87.5% of studies highlighted the benefits of using AI in dermatology, neurology, and pulmonology, highlighting significant cost-effectiveness outcomes, with the most advantageous being a negative cost-effectiveness ratio of –US $27,580 per QALY (quality-adjusted life year) for melanoma diagnosis, indicating substantial cost savings in this scenario. The only study assessing equity, based on 129,819 radiographic images, identified AI-assisted underdiagnosis, particularly in certain subgroups defined by gender, ethnicity, and socioeconomic status. Conclusions: This review underscores the importance of transparency in the description of AI tools and the representativeness of population subgroups to mitigate health disparities. As AI is rapidly being integrated into health care, detailed assessments are essential to ensure that benefits reach all patients, regardless of sociodemographic factors.

11 October 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TBTayná Felicíssimo Gomes de Souza Bandeira
Tayná Felicíssimo Gomes de Souza Bandeira
LMLuciana Marti
Luciana Marti
EREdna T. Rother
Edna T. Rother
LCLucas Reis Correia
Lucas Reis Correia
CMClarisse Martins Martins Machado
Clarisse Martins Martins Machado
Cytomegalovirus (CMV) poses a significant threat to post-hematopoietic cell transplantation (HCT). Control strategies include letermovir prophylaxis or ganciclovir pre-emptive therapy (PET). Without prophylaxis, 65–90% of seropositive recipients develop a clinically significant CMV infection. Due to PET drawbacks, letermovir prophylaxis is preferable, as it reduces CMV-related events and improves overall survival. However, refractory or resistant CMV-CS remains a challenge, with maribavir showing limited efficacy. This systematic review followed the Cochrane Manual and PRISMA guidelines and was registered in PROSPERO. Searches were conducted in PubMed, Scopus, Embase, and Web of Science. Out of 1895 identified records, 614 duplicates were removed, and subsequent screening excluded 1153 studies. Eleven included studies (2012–2024) involved 255 HCT recipients receiving adoptive immunotherapy (AI), primarily CMV-specific T-cell therapy. GvHD occurred in 1.82% of cases. Adverse events occurred in 4.4% of cases, while mild CRS was observed in 1.3% of patients. Efficacy, evaluated in 299 patients across eleven studies, showed an average response rate of 78.2%. CMV-CS recurrence was observed in 24.4% of 213 patients, and death due to CMV was reported in 9.7% of 307 patients across nine studies. Adoptive hCMV-specific T-cell immunotherapy appears to be a safe, effective alternative for refractory CMV-CS in HCT.

30 October 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
AMAna Cláudia Medeiros-De-Souza
Ana Cláudia Medeiros-De-Souza
LLLuana Emanuelly Sinhori Lopes
Luana Emanuelly Sinhori Lopes
BOBruno Zocca de Oliveira
Bruno Zocca de Oliveira
EREdna Terezinha Rother
Edna Terezinha Rother
LCLucas Reis Correia
Lucas Reis Correia
Background: Initiated in 2021, a Brazilian project aims to establish a national injury registry, compiling comprehensive data on events and individuals across the country, irrespective of injury severity. The registry integrates information from prehospital and hospital care, diverse health systems lacking interoperability, and sectors such as firefighters and the police. Its primary goal is to enhance health surveillance by providing timely, high-quality information, guiding prevention strategies, and informing policy making. The project still aims to reduce long-term morbidity and mortality associated with injuries. Objective: A knowledge gap remains regarding the effects of injury registries in relation to policies and injury outcomes. This protocol outlines a systematic review and meta-analysis to answer “What is the effect of implementation and use of injury registry data on policy making, hospitalization, and mortality?” Methods: The systematic review follows PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, focusing on studies reporting results related to the implementation and use of injury registries, including trauma registries. Outcomes of interest include policy making, hospitalization rates or duration, and mortality. Registries within well-defined administrative boundaries will be included. Data will be collected from PubMed, Embase, Scopus, Web of Science, Lilacs, and references. Records will be independently screened by 2 reviewers, with any disagreements resolved through arbitration by a third reviewer. Homogeneous studies, with 3 or more evaluating the same outcome, may undergo meta-analysis. Subgroup analyses by registry type, injury groups, and other selected variables of interest will be conducted. Sensitivity analysis, risk of bias assessment, publication bias evaluation, and quality appraisal will also be performed. Results: This systematic review will run from November 2023 to June 2024. No identical review was found. Search strategies were finalized, the bibliographic search started, duplicates were eliminated, and title and abstract screening began. Of 35 studies retrieved, 85 were excluded due to duplication, leaving 50 for selection. Conclusions: This study is timely, aligning with ongoing national efforts to implement an injury registry. By synthesizing available evidence, we will identify the potential of injury registries to guide the decisions of Brazilian policy makers. Trial Registration: PROSPERO CRD42023481528; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=481528 International Registered Report Identifier (IRRID): PRR1-10.2196/55029

8 August 2025 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
GSGiulia Osório Santana
Giulia Osório Santana
LPLuis Gustavo Nascimento de Paula
Luis Gustavo Nascimento de Paula
LALeandro Seiti Anazawa
Leandro Seiti Anazawa
PNPedro Vieira Santana Netto
Pedro Vieira Santana Netto
AMAline de Souza Moura
Aline de Souza Moura
LCLucas Reis Correia
Lucas Reis Correia
Highlights ■ Vendor Neutral Archive implementation has an return on investment of 5.63% in the first year and 10.12% after three years. ■ At least 11,500 exams are needed annually for a positive return on investment in the first year after implementation. ■ Vendor Neutral Archive enhances interoperability and efficiency by standardizing and centralizing image storage. ■ Scalability is key: higher adoption of Vendor Neutral Archive leads to greater financial and operational benefits. ABSTRACT Objective: To conduct an ex-ante cost-benefit

29 May 2025 in Einstein (São Paulo)
Verified
Journal Article
Open access
PDF file
LCLucas Reis Correia
Lucas Reis Correia
LPLuís Gustavo Nascimento de Paula
Luís Gustavo Nascimento de Paula
JTJulio Trecenti
Julio Trecenti
BSBruno Daleffi da Silva
Bruno Daleffi da Silva
Introduction: Technical Support Centers of the Judiciary (NATJUST), provide health technology assessments to judges in health-related litigations against both public and private healthcare systems. These centers provide technical notes, that can assist Brazilian Courts in making provisional rulings and determining patient access to health services during legal proceedings. Objective: This study aimed to evaluate the impact of NATJUS technical notes on preliminary injunctions in lawsuits against the Brazilian Unified Health System. Specifically, we analyzed the alignment between judicial decisions